Novartis hands PeptiDream $180M upfront to extend radiopharma discovery pact
Novartis is looking to build on its radiopharma research machinery.
The maker of Lutathera and Pluvicto has expanded its longstanding peptide discovery deal with PeptiDream to bolster their work on peptides for conjugation with radionuclide compounds.
The Japanese biotech, which has a long list of drug development partners, will get $180 million upfront and is eligible for up to $2.71 billion in milestones, as well as tiered royalties on net sales of any potential products, according to a Tuesday release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
